menu
    • menu

    Company profile for Sanifit

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA. Sanifit’s lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway t...
    Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA. Sanifit’s lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway that leads to vascular calcification. SNF472 is in clinical development for the treatment of calciphylaxis or CUA (calcific uremic arteriolopathy) in patients undergoing dialysis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SanifitUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3655 Nobel Drive Suite #540 San Diego, CA 92122
    Telephone
    Telephone
    34 971 439 925
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sanifit.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/sanifit-laboratoris
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/sanifitlabs?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanifit lands $231M Vifor buyout ahead of phase 3 data
    Sanifit lands $231M Vifor buyout ahead of phase 3 data

    23 Nov 2021

    // John Carroll ENDPTS

    https://endpts.com/joan-perello-set-out-17-years-ago-to-develop-a-drug-and-today-hes-being-rewarded-with-a-424m-biotech-buyout/

    John Carroll ENDPTS
    23 Nov 2021
    Share Share
    Vifor plumps for a double acquisition
    Vifor plumps for a double acquisition

    23 Nov 2021

    // Elizabeth Cairns EVALUATE

    https://www.evaluate.com/vantage/articles/news/snippets/vifor-plumps-double-acquisition

    Elizabeth Cairns EVALUATE
    23 Nov 2021
    Share Share
    Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment
    Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment

    10 Feb 2021

    // GLOBENEWSWIRE

    http://www.globenewswire.com/fr/news-release/2021/02/10/2173031/0/en/Sanifit-Granted-Orphan-Drug-Designation-by-the-FDA-for-SNF472-for-the-Treatment-of-Peripheral-Arterial-Disease-in-Patients-with-End-stage-Kidney-Disease.html

    GLOBENEWSWIRE
    10 Feb 2021
    Share Share
    Sanifit Presents New Data for SNF472 in Treatment of Vascular at ASN
    Sanifit Presents New Data for SNF472 in Treatment of Vascular at ASN

    23 Oct 2020

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2020-10-23/sanifit-presents-new-data-for-snf472-in-treatment-of-vascular-calcification-at-asn-kidney-week-2020

    PHARMIWEB
    23 Oct 2020
    Share Share
    Sanifit to start new clinical development program of SNF472 in End Stage
    Sanifit to start new clinical development program of SNF472 in End Stage

    20 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/20/2064233/0/en/Sanifit-to-start-new-clinical-development-program-of-SNF472-in-End-Stage-Kidney-Disease-patients-with-Peripheral-Artery-Disease.html

    GLOBENEWSWIRE
    20 Jul 2020
    Share Share
    SNF472 Mechanism of Action data published in British Journal of Pharmacology
    SNF472 Mechanism of Action data published in British Journal of Pharmacology

    25 Jun 2020

    // LUNDBECKFONDEN

    https://www.lundbeckfonden.com/snf472-mechanism-of-action-data-published-in-british-journal-of-pharmacology/

    LUNDBECKFONDEN
    25 Jun 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search